Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Total Current Liabilities data on record, last reported at $120.1 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 16.0% year-over-year to $120.1 million; the TTM value through Dec 2025 reached $120.1 million, up 16.0%, while the annual FY2025 figure was $120.1 million, 16.0% up from the prior year.
  • Total Current Liabilities reached $120.1 million in Q4 2025 per SNDX's latest filing, up from $114.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $120.1 million in Q4 2025 and bottomed at $20.7 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $52.9 million, with a median of $35.0 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: decreased 27.55% in 2022, then skyrocketed 166.03% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $20.7 million in 2021, then skyrocketed by 40.53% to $29.1 million in 2022, then surged by 99.88% to $58.1 million in 2023, then surged by 78.24% to $103.5 million in 2024, then rose by 16.0% to $120.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $120.1 million in Q4 2025, $114.2 million in Q3 2025, and $113.0 million in Q2 2025.